De-risking drug development by early translational pharmacology

Wed20  Oct12:30pm(15 mins)
Where:
Room 3B
Sponsor:
NUVISAN
NUVISAN
Dr Charlotte Kopitz

Abstract

Nuvisan is a fully integrated Science CRO with decades of successful track record in conceiving and executing drug discovery and development programs. In our presentation we show how early and in-depth pharmacological characterization of your asset together with biological evaluation of the corresponding patient segment can help to design the smartest possible way of drug development. Some real-life examples will showcase how to overcome challenges in your drug discovery programs by pharmacological characterization combined with translational research. We will address discovery of combination partners, definition and extension of the clinical indication space, mode of action characterization as well as identification and selection of pharmacodynamic biomarker candidates.
To view the video assoicated with this lecture click here
Youtube

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Login
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021